Share on StockTwits
 

Auxilium Pharmaceuticals (NASDAQ:AUXL) set a new 52-week high during mid-day trading on Friday, StockRatingsNetwork reports. The stock traded as high as $22.54 and last traded at $22.35, with a volume of 504,000 shares. The stock had previously closed at $21.87.

A number of analysts have recently weighed in on AUXL shares. Analysts at Zacks reiterated a “neutral” rating on shares of Auxilium Pharmaceuticals in a research note to investors on Friday, December 20th. They now have a $21.00 price target on the stock. Separately, analysts at MKM Partners reiterated a “buy” rating on shares of Auxilium Pharmaceuticals in a research note to investors on Monday, November 25th. They now have a $24.00 price target on the stock. Finally, analysts at JMP Securities reiterated a “buy” rating on shares of Auxilium Pharmaceuticals in a research note to investors on Monday, November 25th. They now have a $24.00 price target on the stock. Four equities research analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company. Auxilium Pharmaceuticals has a consensus rating of “Buy” and an average target price of $23.21.

Auxilium Pharmaceuticals has a 52-week low of $13.87 and a 52-week high of $22.14. The stock has a 50-day moving average of $20.33 and a 200-day moving average of $18.4. The company has a market cap of $1.117 billion and a P/E ratio of 9.95.

Auxilium Pharmaceuticals (NASDAQ:AUXL) last issued its quarterly earnings data on Wednesday, November 6th. The company reported $0.17 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.15 by $0.02. The company had revenue of $108.10 million for the quarter, compared to the consensus estimate of $103.66 million. During the same quarter in the previous year, the company posted ($0.21) earnings per share. The company’s revenue for the quarter was up 52.3% on a year-over-year basis. Analysts expect that Auxilium Pharmaceuticals will post $0.57 EPS for the current fiscal year.

Auxilium Pharmaceuticals, Inc is a specialty biopharmaceutical company focuses on developing and marketing products to predominantly specialist audiences.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.